公司资料
Cerevel 股价、新闻与催化剂
- 股票代码:
- CERE
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for CERE.
公司概览
业务概览
Cerevel Therapeutics was a neuroscience biotech focused on receptor pharmacology and CNS drug development before being acquired by AbbVie.
所在地与行业分类
Headquartered in the United States and listed on NASDAQ prior to acquisition, it sat in CNS biotechnology.
商业模式特征
The story was built around clinical-stage psychiatry and neurology programs, with valuation tied to pipeline data and strategic interest.
生物医药行业定位
Cerevel was a high-quality neuroscience catalyst name and now belongs to biotech M&A history.
未来催化剂
- Cerevel’s near-term catalyst is mostly transaction resolution and any final closeout / integration-related milestone tied to the company’s acquired pipeline assets. The next update will help show whether the company is moving from promise to a more de-risked stage of execution. Investors will care less about the label than about whether the platform can keep producing credible next steps.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。